Drug Deal Disclosure Act
Summary
The Drug Deal Disclosure Act (S4355) is an early-stage bill requiring HHS to publicly release documents on drug pricing agreements referencing international prices. With no Republican cosponsors and only a committee referral, passage is unlikely. No near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4355 is a transparency bill targeting drug pricing deals, but it is early-stage and lacks bipartisan support.
- 2.No immediate market impact; the bill is unlikely to advance in the 119th Congress.
- 3.Investors should monitor for committee hearings or bipartisan amendments, but currently no actionable signal.
Market Implications
No market implications at this stage. The bill is procedural and has not moved beyond committee referral. Pharmaceutical companies face no immediate disclosure risk. Investors should ignore this bill until it gains bipartisan traction or advances to a floor vote.
Full Analysis
- What happened: On April 21, 2026, Sen. Wyden introduced S4355, the Drug Deal Disclosure Act. It was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill mandates that HHS publicly disclose all records related to most-favored-nation pricing agreements and other confidential drug pricing deals entered into after January 20, 2025, between the federal government and drug manufacturers. 2) The money trail: This is an authorization bill with no funding specified. It imposes a disclosure requirement, not a spending program. Actual enforcement would rely on existing HHS resources. 3) Convergence: No related signals or procurement data were provided beyond a companion bill (HR9699) in the House, which is also in early committee stages. No direct or industry convergence with other government actions is identifiable. 4) Structural winners and losers: The bill targets transparency in drug pricing. If enacted, it could pressure pharmaceutical companies that have entered into international reference pricing agreements, potentially exposing pricing strategies and leading to public pressure for lower prices. However, the bill has no Republican support (all 18 cosponsors are Democrats plus Sen. Sanders), and the 119th Congress is divided. The legislative path is long and uncertain. 5) Timeline: The bill is at the earliest stage—referred to committee. No hearings, markups, or votes scheduled. Passage in this Congress is highly unlikely without bipartisan support.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →